This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Endocrine/metabolic disease				
Diabetes	IL-7 receptor (IL-7R; CD127)	<p>Two studies in mice suggest antagonizing CD127 could help treat type 1 diabetes. In a mouse model of type 1 diabetes, antibodies against CD127 decreased autoimmune T cell activity compared with nonspecific control antibody and prevented disease onset and arrested existing disease. Next steps include preclinical development of humanized anti-CD127 antibodies.</p> <p>Effimune S.A.S.'s MD707, an anti-CD127 antibody, is in preclinical development to prevent transplant rejection.</p> <p>SciBX 5(29); doi:10.1038/scibx.2012.757 Published online July 26, 2012</p>	<p>Findings in first study unpatented; unlicensed</p> <p>Patent applications filed by Pfizer Inc. for findings in second study; unavailable for licensing</p>	<p>Penaranda, C. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online June 25, 2012; doi:10.1073/pnas.1203692109 Contact: Hans Doods, Boston University School of Medicine, Boston, Mass. e-mail: hdooms@bu.edu</p> <p>Lee, L.-F. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online June 25, 2012; doi:10.1073/pnas.1203795109 Contact: John C. Lin, Pfizer Inc., South San Francisco, Calif. e-mail: john.lin@pfizer.com Contact: Li-Fen Lee, same affiliation as above e-mail: li-fen.lee@pfizer.com</p>